HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Markwins Acquires Bonne Bell, Lip Smacker In Bid For Youth Market

This article was originally published in The Rose Sheet

Executive Summary

Deal with Aspire Brands, expected to close this month, will round out Markwins’ portfolio, which includes wet n wild, Physicians Formula and Black Radiance cosmetics, enabling it to cater to “beauty consumers of all demographics, inclusive of age, ethnicity, lifestyle and preference,” the firm says.

You may also be interested in...



People In Brief: New Leadership For Lauder Brands; P&G Beauty Head Moves To Fashion; More

The Estee Lauder Companies, Procter & Gamble, Avon Products and Markwins announce changes to their executive management ranks, and Liz Earle says she will be leaving the natural-oriented brand she co-founded in 1995.

Physicians Formula Goes To Wet N Wild Owner Markwins For $75 Mil.

Markwins International has acquired Physicians Formula Holdings, offering roughly $10 million more than previous suitor Swander Pace Capital. The merger “will strengthen the combined portfolio of brands,” Physicians Formula CEO Ingrid Jackel says.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel